\-\ Texto\\:\\ \ \(0\)\
\-\ n\\/a\ \(127\)\
\-\ incomplete\\.\ \(3\)\
\-\ multiple\\ t2\\ hypointense\\ mass\\ lesions\\ throughout\\ the\\ uterus\\,\\ consistent\\ with\\ leiomyomas\\.\\ \ \(0\)\
\-\ \\ \\-subserosal\ \(0\)\
\-\ \\ \\-intramural\\ \ \(0\)\
\-\ \\ \\-sub\\-mucosal\\ pedunculated\\ within\\ the\\ endometrial\\ cavity\\.\\ \ \(0\)\
\-\ transitional\\ zone\\ diffusely\\ thickened\\ with\\ multiple\\ t2\\ hyerintensities\\ throughout\\ the\\ myometrium\\.\ \(0\)\
\-\ multiple\\ t2\\-bright\\ cystic\\ structures\\ within\\ the\\ cervix\\.\ \(0\)\
\-\ adenomyosis\ \(10\)\
\-\ adenomyosis\ \(10\)\
\-\ endometriosis\ \(26\)\
\-\ leiomyomata\ \(3\)\
\-\ nabothian\\ cysts\ \(0\)\
\-\ the\\ patient\\ reported\\ subjective\\ menorrhagia\\ and\\ dysmenorrhea\\.\\ \\ outside\\ sonofound\\ leiomyomatous\\ uterus\\.\\ \\ interested\\ in\\ uterine\\ artery\\ embolization\\ for\\ relief\\ of\\ her\\ symptoms\\.\ \(0\)\
\-\ the\\ importancce\\ of\\ imaging\\ the\\ uterus\\ prior\\ to\\ performing\\ uterine\\ artery\\ embolization\\ \\(uae\\)\\ is\\ demonstrated\\ in\\ this\\ patient\\ with\\ symptomatology\\ which\\ may\\ be\\ relatable\\ to\\ fibroids\\ or\\ secondary\\ to\\ adenomyosis\\.\\ \\ \\ \\ therapies\\ for\\ adenomyosis\\ include\\ hormonal\\ and\\ hysterectomy\\.\\ \\ uae\\ may\\ be\\ curative\\ for\\ patient\\ with\\ simple\\ fibroid\\ uterus\\ whereas\\ this\\ patient\\ should\\ understand\\ the\\ risk\\ of\\ a\\ nontherapeutic\\ result\\ after\\ uae\\ secondary\\ to\\ unresolved\\ adenomyosis\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ adenomyosis\\:\\ 0\\.1782673097546702\ \(0\)\
\-\ uae\\:\\ 0\\.16921606757096985\ \(0\)\
\-\ uterus\\:\\ 0\\.11188963003290145\ \(0\)\
\-\ \\-subserosal\\:\\ 0\\.06121887794421179\ \(0\)\
\-\ \\-intramural\\:\\ 0\\.06121887794421179\ \(0\)\
\-\ \\-sub\\-mucosal\\:\\ 0\\.06121887794421179\ \(0\)\
\-\ hyerintensities\\:\\ 0\\.06121887794421179\ \(0\)\
\-\ t2\\-bright\\:\\ 0\\.06121887794421179\ \(0\)\
\-\ \\-leiomyomata\\:\\ 0\\.06121887794421179\ \(0\)\
\-\ \\-nabothian\\:\\ 0\\.06121887794421179\ \(0\)\
\-\ sonofound\\:\\ 0\\.06121887794421179\ \(0\)\
\-\ leiomyomatous\\:\\ 0\\.06121887794421179\ \(0\)\
\-\ importancce\\:\\ 0\\.06121887794421179\ \(0\)\
\-\ relatable\\:\\ 0\\.06121887794421179\ \(0\)\
\-\ nontherapeutic\\:\\ 0\\.06121887794421179\ \(0\)\
\-\ uterine\\:\\ 0\\.060898633682266445\ \(0\)\
\-\ \\-adenomyosis\\:\\ 0\\.05640535585698995\ \(0\)\
\-\ \\-endometriosis\\:\\ 0\\.05640535585698995\ \(0\)\
\-\ embolization\\:\\ 0\\.05526717384743084\ \(0\)\
\-\ dysmenorrhea\\:\\ 0\\.05159183376976811\ \(0\)\
\-\ unresolved\\:\\ 0\\.05004222577453054\ \(0\)\
\-\ understand\\:\\ 0\\.048776103852350296\ \(0\)\
\-\ leiomyomas\\:\\ 0\\.046778311682546266\ \(0\)\
\-\ myometrium\\:\\ 0\\.046778311682546266\ \(0\)\
\-\ interested\\:\\ 0\\.045960373934932484\ \(0\)\
\-\ menorrhagia\\:\\ 0\\.0452287036873087\ \(0\)\
\-\ throughout\\:\\ 0\\.04442704619861009\ \(0\)\
\-\ hormonal\\:\\ 0\\.04241297376989089\ \(0\)\
\-\ therapies\\:\\ 0\\.03975330535144571\ \(0\)\
\-\ curative\\:\\ 0\\.03975330535144571\ \(0\)\
\-\ cervix\\:\\ 0\\.03944461255581492\ \(0\)\
\-\ hysterectomy\\:\\ 0\\.03944461255581492\ \(0\)\
\-\ subjective\\:\\ 0\\.03914905967790661\ \(0\)\
\-\ symptomatology\\:\\ 0\\.03833112193029284\ \(0\)\
\-\ fibroids\\:\\ 0\\.038078568845772875\ \(0\)\
\-\ performing\\:\\ 0\\.037834879124861276\ \(0\)\
\-\ pedunculated\\:\\ 0\\.037599451682669045\ \(0\)\
\-\ multiple\\:\\ 0\\.0374959584058181\ \(0\)\
\-\ fibroid\\:\\ 0\\.036730263189932895\ \(0\)\
\-\ transitional\\:\\ 0\\.03633332976048881\ \(0\)\
\-\ artery\\:\\ 0\\.035340694334836095\ \(0\)\
\-\ whereas\\:\\ 0\\.035262838928355064\ \(0\)\
\-\ endometrial\\:\\ 0\\.03364740632232206\ \(0\)\
\-\ t2\\:\\ 0\\.033591510677088224\ \(0\)\
\-\ secondary\\:\\ 0\\.03318097175706677\ \(0\)\
\-\ incomplete\\:\\ 0\\.032019623642885645\ \(0\)\
\-\ zone\\:\\ 0\\.03151980767326697\ \(0\)\
\-\ relief\\:\\ 0\\.030285910609117984\ \(0\)\
\-\ diffusely\\:\\ 0\\.029970199678029396\ \(0\)\
\-\ simple\\:\\ 0\\.0292385294304056\ \(0\)\
\-\ hypointense\\:\\ 0\\.028148225619227373\ \(0\)\
\-\ thickened\\:\\ 0\\.02661049862679279\ \(0\)\
\-\ may\\:\\ 0\\.026032338456918384\ \(0\)\
\-\ cavity\\:\\ 0\\.025974615338421325\ \(0\)\
\-\ outside\\:\\ 0\\.024891734771610496\ \(0\)\
\-\ patient\\:\\ 0\\.023794220303233\ \(0\)\
\-\ cysts\\:\\ 0\\.023246238075217824\ \(0\)\
\-\ structures\\:\\ 0\\.022847676978018847\ \(0\)\
\-\ result\\:\\ 0\\.022765167756583066\ \(0\)\
\-\ within\\:\\ 0\\.022640714005362245\ \(0\)\
\-\ reported\\:\\ 0\\.021632464240109804\ \(0\)\
\-\ n\\/a\\:\\ 0\\.02149449060666032\ \(0\)\
\-\ risk\\:\\ 0\\.02149449060666032\ \(0\)\
\-\ should\\:\\ 0\\.018918114874227777\ \(0\)\
\-\ be\\:\\ 0\\.018302176713110126\ \(0\)\
\-\ her\\:\\ 0\\.017843136517256497\ \(0\)\
\-\ demonstrated\\:\\ 0\\.017412638767062272\ \(0\)\
\-\ cystic\\:\\ 0\\.017115504911470545\ \(0\)\
\-\ include\\:\\ 0\\.016646899222432544\ \(0\)\
\-\ lesions\\:\\ 0\\.015885836849610747\ \(0\)\
\-\ prior\\:\\ 0\\.0152368942514053\ \(0\)\
\-\ for\\:\\ 0\\.01518975309672323\ \(0\)\
\-\ symptoms\\:\\ 0\\.014789288034014855\ \(0\)\
\-\ consistent\\:\\ 0\\.01455068242243891\ \(0\)\
\-\ imaging\\:\\ 0\\.013903290447608352\ \(0\)\
\-\ this\\:\\ 0\\.013349127962696291\ \(0\)\
\-\ after\\:\\ 0\\.012277786129230571\ \(0\)\
\-\ to\\:\\ 0\\.011863003012305173\ \(0\)\
\-\ which\\:\\ 0\\.011077392966962142\ \(0\)\
\-\ mass\\:\\ 0\\.008253201437135864\ \(0\)\
\-\ the\\:\\ 0\\.0076805158168681\ \(0\)\
\-\ or\\:\\ 0\\.006955019090025746\ \(0\)\
\-\ in\\:\\ 0\\.00585273930750354\ \(0\)\
\-\ \\(\\:\\ 0\\.0050164008766934755\ \(0\)\
\-\ \\)\\:\\ 0\\.004955122861897952\ \(0\)\
\-\ is\\:\\ 0\\.00390479707211615\ \(0\)\
\-\ with\\:\\ 0\\.003250116002496937\ \(0\)\
\-\ a\\:\\ 0\\.002754165290406953\ \(0\)\
\-\ \\.\\:\\ 0\\.0027117701185472853\ \(0\)\
\-\ and\\:\\ 0\\.002500125079614145\ \(0\)\
\-\ of\\:\\ 0\\.0024271625166247587\ \(0\)\
\-\ \\,\\:\\ 0\\.0018799310105367178\ \(0\)\
